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Objective: To demonstrate that a combination of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) and Rana
catesbeiana ribonuclease-6 (RC6) exerts synergistic cytotoxic effects on human hepatoma cells.
Materials and Methods: Human hepatoma cells (J5 and HepG2) were treated with various concentrations
of BCNU or RC6. The survival rate was determined by XTT assay. Apoptosis was determined by ﬂuo-
rescence-activated cell sorting analysis with propidium iodide/annexin-V double stain. Caspase activa-
tion was determined by Western blot assay.
Results: BCNU and RC6 are able to inhibit the cell growth of hepatoma cells in a dose-dependent manner.
BCNU combined with RC6 exerts a synergistic cytotoxic effect on hepatoma cells. Normal cells had less
cytotoxicity than on hepatoma cells with BCNU/RC6 treatment. In addition, apoptosis was observed in
hepatoma cells with BCNU treatment, RC6 treatment, and combination treatment. Our data also showed
that combination treatment can activate the caspase-9/caspase-3 cascade obviously in hepatoma cells.
Conclusion: Combination treatment with BCNU and RC6 exerts a synergistic cytotoxic effect on hepatoma
cells.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Hepatocellular carcinoma (HCC) is one of the most common
human tumors worldwide. HCC treatments involve surgery, radi-
ation, and chemotherapy [1e3]. Surgery and radiation are only
effective when tumors are diagnosed at an early stage [4,5].
Although chemotherapy is a conventional method, it has been
associated with cytotoxicities under high-dose treatment [6,7].
Therefore, combination treatment with low-dose drugs has been
considered [8e10].
1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), an alkylating
agent, has been used for tumor treatment [11,12]. Many reports and
our previous study have demonstrated that BCNU can interact with
DNA, RNA, and proteins [13] and can induce DNA crosslinks;
S-phase arrest; downregulation of Bcl-2; inhibition of glutathioneMedicine, Buddhist Tzu Chi
ew Taipei City, Taiwan.
g).
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ddhist Compassion Relief Tzu Chireductase activity; and dysfunction of DNA, RNA, and protein
[14e17]. Based on thesemechanisms, BCNU can affect tumorgenesis
resulting in tumor cell death. However, high dosages of BCNU can
cause many side effects, such as myelosuppression and lung ﬁbrosis
[18,19]. Moreover, previous studies indicated that BCNU can be
detoxiﬁed by glutathione-dependent enzymes and O6-alkylgua-
nine-DNA alkyltransferase, which are found in some hepatoma cells
[20,21]. For these reasons, a combination of BCNU with other drugs
has been investigated for hepatoma therapy [22,23].
RC6 is homologous to onconase and belongs to the ribonuclease
family [24]. These ribonucleases have anticancer effects [25,26].
Onconase has been used as an anticancer drug in clinical trials
[27,28]. Previous studies and our data indicated that the cytotoxic
ribonucleases may affect tumorgenesis by inducing RNA cleavage,
decreasing protein synthesis, inducing mitochondria dysfunction,
and downregulating Bcl-2, Bcl-xL, p53, p21, cyclin, and p16
[9,24,29e31].
Our previous studies have indicated that hepatoma cells are
inhibited by high-dose BCNU alone and high-dose RC6 alone.
However, under these concentrations, BCNU and RC6 are cytotoxic
to normal cells. Therefore, combination treatment with low-doseFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
Fig. 1. BCNU inhibited the cell growth of human hepatoma cells. (A) J5; (B) HepG2; (C) MCF-10A; and (D) WI38 cells were treated with various concentrations of BCNU. After 48
hours of incubation, the survival rates of the treated cells were measured by XTT assay. The results were obtained from four independent triplicate experiments and are presented as
mean SD. ap< 0.05. BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea; SD¼ standard deviation.
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study. Our studies showed that combination treatment with low-
dose BCNU and low-dose RC6 exerts a synergistic cytotoxic effect
on hepatoma cells. Although combined low-dose BCNU and low-
dose RC6 still exerted some cytotoxicity on normal cells, our data
indicated that combination treatment with low-dose BCNU/RC6
was more toxic to hepatoma cells than normal cells. In addition,
combination treatment with BCNU/RC6 can activate the caspase-9/
caspase-3 pathway resulting in apoptosis in hepatoma cells. Over-
all, our study demonstrated that BCNU and RC6 exert a synergistic
cytotoxic effect on hepatoma cells.
2. Materials and methods
2.1. Reagents and cell culture
RC6 was kindly given to us by Dr Jaang-Jiun Wang (Division of
Pediatric Infectious Diseases, Emory University School of Medicine,
Atlanta, USA). Caspase-3, caspase-8, and caspase-9 antibodies were
purchased from Oncogene (Munich, Germany). Actin antibody was
purchased from Millipore (Billerica, MA, USA). Horseradish perox-
idase-conjugated secondary antibodies were purchased from
Sigma (Sigma-Aldrich, St Louis, MO, USA). The annexin-V FLOUS
staining kit and XTT assay kit were obtained from Roche (Roche,
Mannheim, Germany). Polyvinylidene ﬂuoride membrane was
purchased from Amersham Biosciences (Arlington Heights, IL,
USA). HepG2 cells (well-differentiated human hepatoma cells) and
WI38 cells (human ﬁbroblasts) were obtained from Bioresources
Collection and Research Center (BCRC, Hsin Chu, Taiwan) and
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) (GIBCO
BRL, Grand Island, NY, USA). J5 cells (intermediately differentiatedhuman hepatoma cells) were kindly given to us by Dr Jaang-Jiun
Wang and maintained in Rosewell Park Memorial Institute-1640
medium (GIBCO). These cells were supplemented with 10% heat-
inactivated fetal bovine serum (Hyclone Laboratories, Inc., Logan,
UT, USA), 2mM L-glutamine,100 IU/mL penicillin/streptomycin, and
0.1mM nonessential amino acids (GIBCO). MCF-10A (human
epithelial cells) were given to us by Dr Yung-Luen Yu (Graduate
Institute of Cancer Biology and Center for Molecular Medicine,
China Medical University and Hospital, Taichung, Taiwan) and
cultured in DMEM/F12 medium (GIBCO) supplemented with 5%
horse serum, 1% penicillin/streptomycin, 10 mg/mL bovine pancre-
atic insulin, 20 ng/mL epidermal growth factor, and 0.5 mg/mL
hydrocortisone (GIBCO). These cells were cultured at 37C in
a humidiﬁed atmosphere containing 5% CO2.
2.2. Cell survival assay
Cell survival was measured using an XTT assay kit that deter-
mines mitochondrial dehydrogenase activity. Brieﬂy, 5103 cells
were grown in each well of a 96-well plate. On the second day, the
cells were treatedwith various concentrations of BCNU (dissolved in
ethanol) or RC6 (dissolved in PC buffer). XTT assays were carried out
for 2 days according to the manufacturer’s instructions. The absor-
bance at 492 nm and 620 nm was determined using a Microplate
ELISA Reader (Ceres UV900, Bio-TeK Instruments,Winoski, VT, USA).
2.3. Propidium iodide/annexin-V double staining and ﬂuorescence-
activated cell sorting analysis
Apoptosis was determined by using propidium iodide (PI)/
annexin-V staining and a ﬂuorescence-activated cell sorting (FACS)
Fig. 2. RC6 inhibited the cell growth of human hepatoma cells. (A) J5; (B) HepG2; (C) MCF-10A; and (D) WI38 cells were treated with various concentrations of RC6. After 48 hours
of incubation, the survival rates of the treated cells were measured by XTT assay. The results were obtained from four independent triplicate experiments and are presented as
mean SD. ap< 0.05. RC6¼ Rana catesbeiana ribonuclease 6; SD¼ standard deviation.
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tylserine and membrane integrity. Brieﬂy, the cells were stained
with 10 mg/mL annexin V-FLOUS kit and 20 mg/mL PI. After staining,
cells were resuspended in binding buffer at a concentration of
2105 cells/mL before analysis by ﬂow cytometer (Becton Dick-
inson, San Jose, CA, USA). The data were analyzed on WinMDI
version 2.8 software. The percentage of cells undergoing apoptosis
was determined by three independent experiments.2.4. Western blot
Cells were resuspended in lysis buffer (50mM Tris-HCl; 120mM
NaCl; 1mM EDTA; 1% NP-40, pH 7.5) supplemented with protease
inhibitors. Cell lysates were obtained after centrifugation
(15,000g) for 20 minutes at 4C. Cell lysates were run in 13.3%
sodium dodecyl sulfate polyacrylamide gel electrophoresis andFig. 3. BCNU with RC6 synergistically inhibited the cell growth of human hepatoma cells. J5
After 48 hr of incubation, the survival rates of the treated cells were measured by XTT as
presented as mean SD. ap< 0.05. BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea; RC6¼ Ranthen transferred to a polyvinylidene ﬂuoride membrane. After the
membrane was blocked with 5% nonfat milk in Tris buffered saline
with Tween (0.8% NaCl; 0.02% KCl; 25mM Tris-HCl; 0.05% Tween
20, pH 7.4), the membrane was reacted with primary antibodies
(20e50 ng/mL) at 4C overnight. The next day, the membrane was
incubated with biotinylated antimouse immunoglobulin G or
antirabbit immunoglobulin G antibodies (0.5e2 ng/mL), and was
subsequently incubated with streptavidin-horseradish peroxidase
conjugates (0.25 ng/mL). Labeled proteins were visualized by the
Super Signal Chemiluminescent-HRP substrate system (Pierce,
Rockford, IL, USA).2.5. Caspase substrate cleavage activity assay
To analyze the activity of various caspases, cells were lysed with
lysis buffer (50mM Tris-HCl, 120mM NaCl, and 1mM EDTA, 1%(A) and HepG2 cells (B) were treated with indicated concentrations of BCNU and RC6.
say. The results were obtained from four independent triplicate experiments and are
a catesbeiana ribonuclease 6; SD¼ standard deviation.
Table 1












6.25 98 3 90 7 96 5 99 6
12.5 90 7 79 8 92 5 95 7
25 76 7 69 8 87 6 98 8
50 53 8 51 6 79 4 90 6
100 42 4 40 4 63 4 81 7
BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea.
Table 2












20 68 4 73 6 83 5 85 6
40 63 6 71 4 75 6 86 7
80 58 5 67 3 71 5 80 4
160 53 5 53 6 66 3 71 5
320 45 3 49 5 52 3 62 4
RC6¼ Rana catesbeiana ribonuclease 6.
Table 3
The 2-day survival rate of cells treated with 25 mM BCNU and 20 mM RC6
Survival rate HepG2 J5 MCF-10A WI38
Survival rate (%) 36 6 47 5 82 4 86 7
BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea; RC6¼ Ranacatesbeiana ribonuclease6.
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pellets were discarded after centrifugation at 15,000g for 30
minutes at 4C. The caspase activity was assessed in a working
reaction containing 40 mL cell lysate (80 mg total protein), 158 mL
reaction buffer (20% glycerol, 0.5mM EDTA, 5mM dithiothreitol,
100mM HEPES, pH 7.5), and 2 mL ﬂuorogenic substrate, either Ac-
LEHD-pNA or Ac-DEVD-pNA (100 mM ﬁnal concentration); the
reaction was incubated at 37C for 6 hours. Cleavage of the ﬂuo-
rogenic substrate released p-nitroanilide, which was measured at
405 nm in an ultramicroplate reader (Ceres UV 900; Bio-TeK). The
fold increase in caspase activity was calculated using the following
formula: (A405sampleA405control)/A405control.2.6. Statistical analysis
Data were obtained from four independent triplicate experi-
ments and are presented as themean values of the chosen triplicate
groups. These data are shown as means with standard deviations.
The statistical differences were analyzed using student’s t test for
normally distributed values. A value of p less than 0.05 was
considered statistically signiﬁcant.Fig. 4. Combination treatment with BCNU and RC6 did not induce cytotoxic effects on norm
of BCNU and RC6. After 48 hours of incubation, the survival rates of the treated cells were
experiments and are presented as mean SD. BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea3. Results
3.1. BCNU-induced cell cytotoxicity in human hepatoma cells
To determine whether BCNU inhibited cell growth of human
hepatoma cells, both J5 and HepG2 cells were treated with various
concentrations of BCNU for 2 days. As shown in Fig. 1, BCNU was
able to induce cytotoxicity in both types of cells and this effect was
dose-dependent manner. The 2-day survival rate was below 50%
only when cells were treated with 50e100 mM BCNU. However the
2-day survival rate was above 70% when cells were treated with
0e25 mM BCNU. That is, BCNU in the range 50e100 mM BCNU was
able to effectively inhibit the cell growth of both types of hepatoma
cells, but no obvious cytotoxicity was observed in hepatoma cells
with 6.25e25 mM BCNU treatment.3.2. RC6-induced cell cytotoxicity in human hepatoma cells
To further clarify whether RC6 inhibited the cell growth of
human hepatoma cells, both J5 and HepG2 cells were treated with
various concentrations of RC6 for 2 days. Our studies showed that
RC6 was able to induce cytotoxicity in both types of cells and this
effect was dose-dependent (Fig. 2), similar to the BCNU-induced
cytotoxicity shown in Fig. 1. Our experiments also showed that only
160e320 mM RC6 was able to effectively inhibit the cell growth of
both types of hepatoma cells resulting in a 2-day survival rate
below 50%. Observations from Figs. 1 and 2 suggest that the cell
growth of both J5 and HepG2 could be inhibited effectively when
cells were treated with higher dosages of BCNU or RC6 alone.3.3. Combination treatment with low-dose BCNU and RC6 exerted
a synergistic cytotoxic effect in human hepatoma cells
RC6 treatments with dosages less than 80 mM inhibited the cell
growth of normal cells (data not shown). To inhibit cell growth of
hepatoma cells effectively using lower dosages of BCNU and RC6,
combination treatment with BCNU and RC6 was applied in hepa-
toma cells. As shown in Figs. 1 and 2, the 2-day survival rates were
above 70% in both J5 and HepG2 cells with 25 mM BCNU and 20 mMal cells. (A) MCF-10A and (B) WI38 cells were treated with the indicated concentrations
measured by XTT assay. The results were obtained from four independent triplicate
; RC6¼ Rana catesbeiana ribonuclease 6; SD¼ standard deviation.
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with lower dosages of BCNU and RC6 has a synergistic cytotoxic
effect on hepatoma cells, both J5 and HepG2 cells were exposed to
BCNU alone, RC6 alone, and BCNU/RC6. Our results showed that
the survival rate was about 70% in both types of cells treated with
25 mM BCNU and 20 mM RC6 alone (Fig. 3). However, combination
treatment with 25 mM BCNU and 20 mM RC6 resulted in about
a 40% survival rate (Fig. 3). Our data suggest that combination
treatment with lower dosages of BCNU or RC6 exerts a synergistic
cytotoxic effect on human hepatoma cells. In addition, as shown inFig. 5. (A) Apoptosis was induced in HepG2 cells with BCNU or RC6 treatment. Cells were do
FACS analysis; (B) The original FACS analysis diaphragms. ap< 0.05. BCNU¼ 1,3-bis(2-chloro
RC6¼ Rana catesbeiana ribonuclease 6.Tables 1e3, the survival rates were below 50% when HCC cells
(HepG2 and J5) were treated with 100 mM BCNU alone or 320 mM
RC6 alone. However, when MCF-10A and WI38 cells were treated
with 100 mM BCNU, the survival rates were about 63% and 80%
(Table 1). When MCF-10A andWI38 cells treated with 320 mMRC6,
the survival rates were around 52% and 62%, respectively (Table 2).
HCC cells had survival rates below 50% with a combination of
25 mM BCNU and 20 mM RC6. Nevertheless, the survival rates of
MCF-10A and WI38 cells exceeded 80% with this combination
treatment. (Fig. 4 and Table 3).uble stained with PI/annexin-V, and the percentage of apoptosis was determined with
ethyl)-1-nitrosourea; FACS¼ ﬂuorescence-activated cell sorting; PI¼ propidium iodide;
Fig. 7. Caspase-9 and caspase-3 activity were determined in HepG2 cells treated with
25 mM BCNU, 20 mM RC6, and a combination of 25 mM BCNU and 20 mM RC6. Note that
caspase-9/caspase-3 activity was signiﬁcantly increased in the combination treatment.
The results are presented as mean SD from four independent triplicate experiments.
BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea; RC6¼ Rana catesbeiana ribonuclease 6;
SD¼ standard deviation.
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caspase-3 cascade in hepatoma cells
After 2 days treatment with a single agent or combined treat-
ment, HepG2 cells were collected and double stainedwith annexin-
V/PI for FACS analysis. The percentage of apoptosis induced by
BCNU and RC6 was about 17% and 20%, respectively (Fig. 5).
However, combined exposure with BCNU and RC6 resulted in up to
50% apoptosis (Fig. 5). To further demonstratewhether the caspase-
9/caspase-3 or caspase-8/caspase-3 cascade was induced in HepG2
cells with combination treatment, caspase-3, caspase-8, and cas-
pase-9 activities were measured by Western blot (Fig. 6). After
HepG2 cells were treated with a combination of BCNU and RC6,
procaspase-9 was decreased and cleaved, but caspase-3 increased
(Fig. 6, Lanes 4). However, there was no obvious decrease in pro-
caspase-8 (Fig. 6). Moreover, caspase-9 and caspase-3 activities
were found in combination treatment with BCNU and RC6 by
substrate cleavage assay (Fig. 7). The apoptosis percentage and
caspase activation were determined in J5 cells. Our study showed
that J5 cells exposed to a combination of BCNU and RC6 had results
similar to those for the HepG2 cells exposed to a combination of
BCNU and RC6 (data not showed).4. Discussion
Previously, Liao et al [24] showed that 20 mM RC6 has a strong
cytotoxic effect on cervical cancers. However, our data showed that
the 2-day survival rate was about 70% in J5 and HepG2 hepatoma
cells with 20 mMRC6 treatment (Fig. 2). That is, RC6 is more toxic to
cervical cancers than hepatoma cells. We suggest that RC6 has
a different cytotoxic effect on different cell lines. In addition, our
data showed that a high dosage of RC6 (160e320 mM) could
effectively inhibit the growth of hepatoma cells (Fig. 2) and also the
growth of normal cells. Therefore, we focused on the use of low-
dose RC6 for hepatoma cell therapy.
BCNU has been used as a clinical anticancer drug [11,12].
Hepatoma cells could be inhibited under high dosage BCNUFig. 6. Caspase activation was determined by Western blotting analysis. HepG2 cells
were treated either with diluent (Lane 1), 25 mM BCNU (Lane 2), 20 mM RC6 (Lane 3) or
25 mM BCNU, and 20 mM RC6 (Lane 4). Two days after treatment, cells were lysed and
subjected to SDS-PAGE followed by Western blotting analysis using antibodies against
procaspase-8, procaspase-9, or procaspase-3. Actin served as a loading control.
BCNU¼ 1,3-bis(2-chloroethyl)-1-nitrosourea; RC6¼ Rana catesbeiana ribonuclease 6;
SDS-PAGE¼ sodium dodecyl sulfate polyacrylamide gel electrophoresis.treatment (Fig. 1). Similar results were also demonstrated in
a previous study [10].
To avoid the side effects caused by high-dosage treatment,
a combination treatment with low-dose BCNU and RC6 was
considered in this study. As shown in Fig. 3, combination treatment
with 25 mMBCNU and 20 mMRC6 had a strong synergistic cytotoxic
effect on hepatoma cells. Previous studies and our primary data
indicated that RC6 can cleave RNA, inhibit protein synthesis, and
downregulate Bcl-2 and Bcl-xL [9,24,31]. BCNU can interact with
DNA, RNA, and protein; induce DNA crosslinks and S-phase arrest;
and inhibit cell division [13e17]. These mechanisms are factors in
RC6/BCNU-induced cell death and can explain why RC6 and BCNU
exert synergistic cytotoxic effects.
Cell death has been divided into the apoptosis and necrosis
pathways [33]. DNA condensation, fragmentation, and the pres-
ence of phosphatidyl serine in the outer membrane are the
major characteristics of apoptosis [9,10]. In this study, phospha-
tidyl serine was detected in the outer membrane in BCNU/
RC6-treated hepatoma cells by annexin-V/PI analysis (Fig. 5).
Therefore, combination treatment with BCNU and RC6 can induce
apoptosis in hepatoma cells. In addition, many studies have
shown that the caspase-3/caspase-8 and caspase-3/caspase-9
cascades are the major caspase pathways [34,35]. In the Western
blot, caspase-9 and caspase-3 activities were induced and cas-
pase-8 activity was not activated in BCNU/RC6 treated-hepatoma
cells (Figs. 6 and 7). We suggest that combination treatment
with BCNU and RC6 induces apoptosis through the caspase-9/
caspase-3 cascade.
This study is the ﬁrst to demonstrate that combination treat-
ment with low-dose BCNU and RC6 has a synergistic cytotoxic
effect on hepatoma cells and induces apoptosis through the cas-
pase-9/caspase-3 cascade in hepatoma cells.
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